L
Lionnel Geoffrois
Researcher at University of Lorraine
Publications - 108
Citations - 4253
Lionnel Geoffrois is an academic researcher from University of Lorraine. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 89 publications receiving 2988 citations. Previous affiliations of Lionnel Geoffrois include Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen,Denis Soulières,Christophe Le Tourneau,Christophe Le Tourneau,Christophe Le Tourneau,José Dinis,Lisa Licitra,Myung-Ju Ahn,Ainara Soria,Jean-Pascal Machiels,Jean-Pascal Machiels,Nicolas Mach,Ranee Mehra,Barbara Burtness,Pingye Zhang,Jonathan D. Cheng,Ramona F. Swaby,Kevin J. Harrington,Kevin J. Harrington,Mirelis Acosta-Rivera,Douglas Adkins,Morteza Aghmesheh,Mario Airoldi,Eduardas Aleknavicius,Yousuf Al-Farhat,Alain Algazi,Salah Almokadem,Anna Alyasova,Jessica Bauman,Marco Benasso,Alfonso Berrocal,Victoria Bray,Barbara Ann Burtness,F. Caponigro,Ana Castro,Terrence P. Cescon,Kelvin K. W. Chan,Arvind Chaudhry,Bruno Chauffert,Ezra W. Cohen,Tibor Csoszi,J. de Boer,Jean-Pierre Delord,Andreas Dietz,Charlotte Dupuis,Laurence Digue,Jozsef Erfan,Yolanda Alvarez,Mererid Evans,Mary J. Fidler,Martin David Forster,Signe Friesland,Apar Kishor Ganti,Lionnel Geoffrois,Cliona Grant,Viktor Gruenwald,Kevin J. Harrington,Thomas K. Hoffmann,Geza Horvai,Arturas Inciura,Raymond Woo-Jun Jang,Petra Jankowska,Antonio Jimeno,Mano Joseph,Alejandro Juarez Ramiro,Boguslawa Karaszewska,Andrzej Kawecki,Ulrich Keilholz,Ulrich Keller,Sung Bae Kim,Judit Kocsis,Nuria Kotecki,Mark F. Kozloff,Julio Lambea,Laszlo Landherr,Yuri Lantsukhay,Sergey Alexandrovich Lazarev,Lip Way Lee,Igor Dmitrievich Lifirenko,Danko Martincic,Oleg Vladmirovhich Matorin,Margaret McGrath,Krzysztof Misiukiewicz,John C. Morris,Fagim Fanisovich Mufazalov,Jiaxin Niu,Devraj Pamoorthy Srinivasan,Pedro Perez Segura,Daniel Rauch,Maria Leonor Ribeiro,Cristina P. Rodriguez,Frederic Rolland,Antonio Russo,Agnes Ruzsa,Frederico Sanches,Sang-Won Shin,Mikhail Shtiveland,Pol Specenier,Eva Szekanecz,Judit Szota,Carla M.L. van Herpen,Hector A. Velez-Cortes,William V. Walsh,Stefan Wilop,Ralph Winterhalder,Marek Z. Wojtukiewicz,Deborah Wong,Dan P. Zandberg +107 more
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.
Journal ArticleDOI
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Arnaud Mejean,Alain Ravaud,Simon Thezenas,Sandra Colas,Jean-Baptiste Beauval,Karim Bensalah,Lionnel Geoffrois,Antoine Thiery-Vuillemin,Luc Cormier,Herve Lang,Laurent Guy,G. Gravis,Frederic Rolland,Claude Linassier,Eric Lechevallier,Christian Beisland,Michael Aitchison,Stéphane Oudard,Jean-Jacques Patard,Christine Theodore,Christine Chevreau,B. Laguerre,Jacques Hubert,Marine Gross-Goupil,Jean-Christophe Bernhard,Laurence Albiges,Marc-Olivier Timsit,Thierry Lebret,Bernard Escudier +28 more
TL;DR: Sunitinib alone was not inferior to nephrectomy followed by sunit inib in patients with metastatic renal‐cell carcinoma who were classified as having intermediate‐risk or poor‐risk disease.
Journal ArticleDOI
Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy
J.L. Lefebvre,Frederic Rolland,M. Tesselaar,Etienne Bardet,Charles R. Leemans,Lionnel Geoffrois,P. Hupperets,L. Barzan,D. De Raucourt,D. Chevalier,Lisa Licitra,F. Lunghi,Roger Stupp,Denis Lacombe,Jan Bogaerts,J.C. Horiot,Jacques Bernier,Jan B. Vermorken +17 more
TL;DR: Larynx preservation, progression-free interval, and overall survival were similar in both arms, as were acute and late toxic effects.
Journal ArticleDOI
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier,Gwenaelle Gravis,David Pérol,Christine Chevreau,Remy Delva,Jacques-Olivier Bay,Ellen Blanc,Celine Ferlay,Lionnel Geoffrois,Frederic Rolland,Eric Legouffe,Emmanuel Sevin,Brigitte Laguerre,Bernard Escudier +13 more
TL;DR: The toxicity of the temsirolimus and bevacizumab combination was much higher than anticipated and limited treatment continuation over time, and this combination cannot be recommended for first-line treatment in patients with metastatic renal cell carcinoma.
Journal ArticleDOI
Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
Stéphane Culine,P. Kerbrat,Andrew Kramar,Christine Theodore,Christine Chevreau,Lionnel Geoffrois,N.B. Bui,J. Peny,A. Caty,Remy Delva,P. Biron,Karim Fizazi,J. Bouzy,J.P. Droz +13 more
TL;DR: 3BE500P is the treatment of choice for metastatic NSGCT patients with bleomycin, etoposide and cisplatin and similar nonsignificant trends were observed in good IGCCCG prognosis patients.